

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

Rat Anti-Mouse CD107a Monoclonal Antibody, PE Conjugated, Clone 1D4B

RRID:AB_1645247

Type: Antibody

Proper Citation

BD Biosciences Cat# 558661, RRID:AB_1645247

Antibody Information

URL: http://antibodyregistry.org/AB_1645247

Proper Citation: BD Biosciences Cat# 558661, RRID:AB_1645247

Target Antigen: Mouse CD107a

Host Organism: rat

Clonality: monoclonal

Comments: Intracellular staining (flow Cytotoxicityometry)

Antibody Name: Rat Anti-Mouse CD107a Monoclonal Antibody, PE Conjugated, Clone 1D4B

Description: This monoclonal targets Mouse CD107a

Target Organism: mouse

Clone ID: Clone 1D4B

Antibody ID: AB_1645247

Vendor: BD Biosciences

Catalog Number: 558661

Record Creation Time: 20231110T052329+0000

Record Last Update: 20260829T203110+0000

Ratings and Alerts

No rating or validation information has been found for Rat Anti-Mouse CD107a Monoclonal Antibody, PE Conjugated, Clone 1D4B.

No alerts have been found for Rat Anti-Mouse CD107a Monoclonal Antibody, PE Conjugated, Clone 1D4B.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang L, et al. (2026) Triple-armed oncolytic HSV enhances antitumor immunity by remodeling the tumor microenvironment in subcutaneous murine CRC. *iScience*, 29(6), 115883.

Fremuth LE, et al. (2025) Neuraminidase 1 regulates neuropathogenesis by governing the cellular state of microglia via modulation of Trem2 sialylation. *Cell reports*, 44(1), 115204.

Rennen S, et al. (2025) Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways. *Cell reports*, 44(8), 116150.

Fan Y, et al. (2025) Adoptive macrophages suppress glioblastoma growth by reversing immunosuppressive microenvironment through programmed phenotype repolarization. *Cell reports*, 44(10), 116350.

Nikolic I, et al. (2025) Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. *Cancer cell*.

Sudholz H, et al. (2025) Core fucosylation of IL-2RB is required for natural killer cell homeostasis. *Cell reports*, 44(8), 116101.

Bedrosian ZK, et al. (2025) NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity. *Journal of immunology (Baltimore, Md. : 1950)*, 214(6), 1410.

Oh JH, et al. (2025) Naturalized immune responses are stable over years in a colony of laboratory mice with wild-derived microbiota. *Immunity*, 58(9), 2305.

Seo D, et al. (2024) Poxvirus A51R proteins regulate microtubule stability and antagonize a cell-intrinsic antiviral response. *Cell reports*, 43(3), 113882.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Sudholz H, et al. (2024) DOT1L maintains NK cell phenotype and function for optimal tumor control. *Cell reports*, 43(6), 114333.

Vetters J, et al. (2023) Canonical IRE1 function needed to sustain vigorous natural killer cell proliferation during viral infection. *iScience*, 26(12), 108570.

Wenes M, et al. (2022) The mitochondrial pyruvate carrier regulates memory T_H1 cell differentiation and antitumor function. *Cell metabolism*, 34(5), 731.

Wenzek C, et al. (2022) CD47 restricts antiviral function of alveolar macrophages during influenza virus infection. *iScience*, 25(12), 105540.

Mah-Som AY, et al. (2021) Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. *Cell reports*, 35(9), 109209.

Funato Y, et al. (2020) The Oncogenic PRL Protein Causes Acid Addiction of Cells by Stimulating Lysosomal Exocytosis. *Developmental cell*, 55(4), 387.

Milner JJ, et al. (2020) Heterogenous Populations of Tissue-Resident CD8⁺ T Cells Are Generated in Response to Infection and Malignancy. *Immunity*, 52(5), 808.

Segovia M, et al. (2019) Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. *Cancer cell*, 35(5), 767.